The Role Of Erythropoietin In The Treatment Of Anemia In Patients With Malignant Lymphoma

1. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin - an updated overview. Nature Clinical Practice Oncology. 2006;3:152-154.10.1038/ncponc0451Search in Google Scholar

2. Nagy J, Kiss I. Az eritropoetin pleiotrop hatásai. LAM. 2007;17(12):861-867.Search in Google Scholar

3. Aapro M, Österborg A, Gascón P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron defi ciency and the specifi c role of i.v. iron. Annals of Oncology. 2012;23:1954-1962.10.1093/annonc/mds112Search in Google Scholar

4. Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD007303. DOI: 10.1002/14651858.CD007303.pub2.10.1002/14651858.CD007303.pub2Search in Google Scholar

5. Barrett-Lee PJ, Ludwig H, Birgegård G. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anemia Survey. Oncology. 2006;70:34-48.10.1159/000091675Search in Google Scholar

6. Birgegård G, Aapro MS, Bokemeyer C. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology. 2005;68(Suppl 1): 3-11.10.1159/000083128Search in Google Scholar

7. Thomas ML. Impact of anemia and fatigue on quality of life in cancer patients; A brief review. Med Oncol. 1998;15:53-57.Search in Google Scholar

8. Shasha D, George MJ, Harrison LB. Once weekly dosing of epoetin increases hemoglobin and quality of life in anemic cancer patient receiving radiation therapy either concomitently or sequentially with chemoterapy. Cancer. 2003;98:1072-1079.10.1002/cncr.11616Search in Google Scholar

9. Miller Carole B, Jones RJ, Piantados S, Abeloff MD, Spivak JL. Decreased Erythropoietin Response in Patients with the Anemia of Cancer, M.D. N Engl J Med. 1990;322:1689-1692.Search in Google Scholar

10. Engert A, Josting A, Haverkamp H, et al. Epoetin Alfa in Patients With Advenced-Stage Hodgkin’s Lymphoma. Results of the Randomized Placebo- Controled GHSG, HD15 EPO Trial. J Clin Oncol. 2010;28(13):2239-2245.10.1200/JCO.2009.25.1835Search in Google Scholar

11. Spivak JL, Gascon P, Ludwig H. Anemia Management in Oncology and Hematology. The Oncologist. 2009;14(S1):43-56.10.1634/theoncologist.2009-S1-43Search in Google Scholar

12. Coiffi er B. Anemia associated with non-platinum chemotherapy (CT) for Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL). European Journal of Cancer. 1999;35:S331.10.1016/S0959-8049(99)81747-XSearch in Google Scholar

13. Campos MPO, Hassan BJ, Riechelmann R, Del Giglio A. Cancer-related fatigue: a practical review. AnnOncol. 2011;22(6):1273-1279.10.1093/annonc/mdq45821325448Search in Google Scholar

14. Littlewood TJ. Erythropoietin for the treatment of anemia associated with hematological malignancy. Hematological Oncology. 2001;19(1):19-30.10.1002/hon.66311276043Search in Google Scholar

15. Truong Pauline T, Parhar Tarnjit BS, Hart J, Alexander Cheryl, Wai Elaine S. Population-Based Analysis of the Frequency of Anemia and its Management Before and During Chemotherapy in Patients With Malignant Lymphoma. American Journal of Clinical Oncology. 2010;33(5):465-468.10.1097/COC.0b013e3181b4b14719935386Search in Google Scholar

16. Pirker R. Safety considerations for erythropoietin treatment in patients with cancer, Expert Opinion on Drug Safety. 2007;6(1):63-69.Search in Google Scholar

17. Deger M, Eisterer W, Kutikova Lucie, Salek S. Hemoglobin level at initiation of darbopoetin alfa: impact on need for transfusion and associated costs in chemoterapy-induced anemia treatment in Europe. Supportive Care in Cancer. 2013;21:485-493.10.1007/s00520-012-1538-0353802222825456Search in Google Scholar

18. Schrijvers D, Samblanx H, Roila F. Erythropoiesis stimulating agents in the treatment of cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol. 2010;21(Suppl 5):244-247.10.1093/annonc/mdq20220555090Search in Google Scholar

19. Carson JL, Grossmann BJ, Kleinmann S, et al. Red blood cell transfusion: a clinical practice guaidline from the AABB. Ann Intern Med. 2012;157: 49-58.10.7326/0003-4819-157-1-201206190-0042922751760Search in Google Scholar

20. Eisterer W, Hussl C, Erb H, et al. Evaluating the transfusion rate with darbepoetin alfa 500 microg every 3 weeks in anemic cancer patients receiving chemotherapy. Cur Med Res Opin. 2011;27:355-363.10.1185/03007995.2010.54213421166611Search in Google Scholar

21. Canon JL, Vansteenkiste J, Hedenus M, et al. Transfusion risk in cancer patients with chemoterapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobine level of <9 /g/dL versus 9 to 10g/ dL versus ≥ 10g/dL: an exploratory analysis of a phase 3 trial. Med Oncol. 2011, doi: 10.1007/s12032-011-0103-x. 10.1007/s12032-011-0103-x22081263Search in Google Scholar